Scarica l'app Stockscreener
109.73
4.24%
-4.86
Pre-mercato:
108.59
-1.14
-1.04%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GH Giù?
Forum
Previsione
Precedente Chiudi:
$114.59
Aprire:
$114.86
Volume 24 ore:
1.60M
Relative Volume:
0.65
Capitalizzazione di mercato:
$14.25B
Reddito:
$902.57M
Utile/perdita netta:
$-398.79M
Rapporto P/E:
-34.15
EPS:
-3.2131
Flusso di cassa netto:
$-274.52M
1 W Prestazione:
-5.20%
1M Prestazione:
+6.55%
6M Prestazione:
+147.87%
1 anno Prestazione:
+127.37%
Intervallo 1D:
$109.25
$115.25
Intervallo di 1 settimana:
$109.25
$120.74
Portata 52W:
$34.88
$120.74
Guardant Health Inc Stock (GH) Company Profile
Nome
Guardant Health Inc
Settore
Industria
Telefono
855-698-8887
Indirizzo
3100 HANOVER STREET, PALO ALTO
Confronta GH con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
109.73 | 14.88B | 902.57M | -398.79M | -274.52M | -3.2131 |
|
TMO
Thermo Fisher Scientific Inc
|
608.02 | 234.41B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
224.54 | 166.52B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
687.74 | 55.48B | 4.17B | 1.03B | 940.22M | 12.61 |
|
IQV
Iqvia Holdings Inc
|
239.76 | 41.05B | 15.90B | 1.28B | 2.21B | 7.2842 |
|
A
Agilent Technologies Inc
|
133.87 | 38.54B | 6.95B | 1.30B | 1.15B | 4.5696 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-05 | Downgrade | Evercore ISI | Outperform → In-line |
| 2025-12-02 | Ripresa | Morgan Stanley | Overweight |
| 2025-09-25 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-09-22 | Ripresa | Wells Fargo | Overweight |
| 2025-04-10 | Iniziato | Mizuho | Outperform |
| 2025-01-23 | Iniziato | Barclays | Overweight |
| 2024-06-28 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-04-24 | Ripresa | Craig Hallum | Buy |
| 2023-12-14 | Iniziato | Guggenheim | Neutral |
| 2023-12-13 | Iniziato | Wolfe Research | Peer Perform |
| 2023-11-13 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-09-28 | Iniziato | Bernstein | Outperform |
| 2023-09-27 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-05-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-05-05 | Iniziato | UBS | Buy |
| 2023-03-09 | Downgrade | Citigroup | Buy → Neutral |
| 2023-01-05 | Iniziato | Scotiabank | Sector Outperform |
| 2022-11-01 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-10-19 | Iniziato | Craig Hallum | Buy |
| 2022-10-06 | Iniziato | Stephens | Overweight |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-06-03 | Iniziato | Piper Sandler | Overweight |
| 2022-04-28 | Ripresa | BTIG Research | Buy |
| 2022-02-24 | Reiterato | Canaccord Genuity | Buy |
| 2022-02-24 | Reiterato | Citigroup | Buy |
| 2022-02-24 | Reiterato | Cowen | Outperform |
| 2022-02-24 | Reiterato | Morgan Stanley | Overweight |
| 2022-02-24 | Reiterato | SVB Leerink | Outperform |
| 2022-02-24 | Reiterato | Stifel | Buy |
| 2022-02-24 | Reiterato | Wells Fargo | Overweight |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-06-15 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-03 | Iniziato | Goldman | Buy |
| 2021-05-25 | Iniziato | Wells Fargo | Overweight |
| 2021-01-11 | Iniziato | Stifel | Buy |
| 2020-09-09 | Iniziato | Morgan Stanley | Overweight |
| 2020-06-12 | Iniziato | BTIG Research | Buy |
| 2020-02-21 | Iniziato | Guggenheim | Buy |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-08-07 | Reiterato | Canaccord Genuity | Buy |
| 2019-04-16 | Iniziato | Canaccord Genuity | Buy |
| 2019-04-10 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-02-28 | Reiterato | BofA/Merrill | Neutral |
| 2018-10-29 | Iniziato | BofA/Merrill | Neutral |
| 2018-10-29 | Iniziato | JP Morgan | Overweight |
| 2018-10-29 | Iniziato | William Blair | Outperform |
Mostra tutto
Guardant Health Inc Borsa (GH) Ultime notizie
Merger Talk: What are the future prospects of Guardant Health IncWeekly Loss Report & Daily Profit Maximizing Tips - baoquankhu1.vn
Risk Analysis: Does Tripadvisor Inc have declining or rising EPSJuly 2025 Reactions & Precise Buy Zone Tips - baoquankhu1.vn
Guardant Health Inc (GH) Shares Down 3.74% on Jan 28 - GuruFocus
Is There An Opportunity With Guardant Health, Inc.'s (NASDAQ:GH) 23% Undervaluation? - 富途牛牛
Analysts Are Bullish on These Healthcare Stocks: Guardant Health (GH), Regeneron (REGN) - The Globe and Mail
Guggenheim Raises Price Target on Guardant Health (GH) to $135 | GH Stock News - GuruFocus
Guardant Health: Look For Explosive Revenue Growth Ahead (NASDAQ:GH) - Seeking Alpha
Y Intercept Hong Kong Ltd Has $4.77 Million Holdings in Guardant Health, Inc. $GH - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: Vaxcyte (PCVX), Guardant Health (GH) - The Globe and Mail
Universal Beteiligungs und Servicegesellschaft mbH Acquires 106,263 Shares of Guardant Health, Inc. $GH - MarketBeat
Baillie Gifford & Co. Increases Position in Guardant Health, Inc. $GH - MarketBeat
Guardant Health (GH): Court Decision Offers Incremental Positive in Litigation - GuruFocus
Leerink Partners Maintains Guardant Health(GH.US) With Buy Rating - 富途资讯
Guardant Can Try Again To Nix Patent Tied To $83M Verdict - Law360
Wall Street Has a Positive Opinion on Guardant Health (GH) - Finviz
Guardant Health, Inc. $GH is Emerald Mutual Fund Advisers Trust's 8th Largest Position - MarketBeat
Insider Sell: Terilyn Monroe Sells 8,571 Shares of Guardant Heal - GuruFocus
Guardant Health CPO Monroe sells $977k in stock By Investing.com - Investing.com UK
Guardant Health (NASDAQ:GH) Insider Sells $977,865.39 in Stock - MarketBeat
Guardant Health CPO Monroe sells $977k in stock - Investing.com
Avoiding Lag: Real-Time Signals in (GH) Movement - Stock Traders Daily
AI Diagnostics Co.'s Patent Claims Don't Pass Alice Test - Law360
FDA Approves Guardant Health's Blood Test To Guide Treatment For Advanced Colorectal Cancer - Benzinga
Analysts turn more bullish on Guardant Health, Inc. (GH) as 2026 growth catalysts build - MSN
Guardant Health, Inc. Receives FDA Approval for Guardant360®? CDx as Companion Diagnostic for BRAFTOVI®? (Encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer - marketscreener.com
FDA Approves Guardant Health's (GH) Diagnostic for Colorectal Ca - GuruFocus
FDA Approval Boosts Guardant Health (GH) with New Diagnostic Use - GuruFocus
Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer - Yahoo Finance
Guardant Health, Inc. $GH Shares Bought by Emerald Advisers LLC - MarketBeat
Guardant Health (NASDAQ:GH) Hits New 12-Month HighHere's Why - MarketBeat
Is Merck’s Guardant Liquid Biopsy Alliance Reshaping the Investment Case for MRK? - Yahoo Finance
Strong Results and Improved Guidance Lifted Guardant Health (GH) in Q4 - Insider Monkey
Inspire Advisors LLC Makes New Investment in Guardant Health, Inc. $GH - MarketBeat
Guardant Health, Inc. (NASDAQ:GH) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Analysts Turn More Bullish on Guardant Health, Inc. (GH) as 2026 Growth Catalysts Build - Insider Monkey
Guardant Health’s Shield Blood Test for Colorectal Cancer Screening Now Available for U.S. Military Members and Families in North Carolina - New Bern Live
Guardant Health (GH) Joins Forces with Merck for Oncology Advancements - GuruFocus
Guardant Health announces multi-year strategic collaboration agreement with Merck for companion diagnostics - BioSpectrum Asia
Guardant Health Announces Multi-Year Strategic Collaboration Agreement With Merck - TradingView — Track All Markets
Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform - Chartmill
Campbell & CO Investment Adviser LLC Makes New $1.19 Million Investment in Guardant Health, Inc. $GH - MarketBeat
Guardant Health, Inc. (GH) Stock Analysis: Unlocking Potential in Precision Oncology with a Robust Revenue Growth - DirectorsTalk Interviews
Guardant Health: Shield Colorectal Cancer Screening To Sustain Growth - Seeking Alpha
Guardant Health stock hits 52-week high at 113.98 USD By Investing.com - Investing.com Nigeria
IPO Launch: How does Guardant Health Inc compare to its peersJuly 2025 Reactions & Daily Profit Maximizing Tips - baoquankhu1.vn
Guardant Health stock hits 52-week high at 113.98 USD - Investing.com India
Sumitomo Mitsui Trust Group Inc. Has $47.12 Million Position in Guardant Health, Inc. $GH - MarketBeat
Global Pan-Genomic and Multi-Gene Panel Testing Market Forecast to Hit US$ 25.91 Billion by 2032 at 12.04% CAGR, Driven by Growing Demand for Comprehensive Multi-Gene Diagnostics: AnalystView Market Insights - GlobeNewswire Inc.
BLOODPAC Publishes New Standards for Liquid Biopsy Tests That Monitor for Cancer Recurrence - PA Media
Guardant Health (NASDAQ:GH): Strongest Q3 Results from the Testing & Diagnostics Services Group - Yahoo Finance
Guardant Health Announces Strong 2025 Preliminary Revenue Growth - The Globe and Mail
Guardant Health Inc Azioni (GH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.14%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):